AI eye on stomach cancer: 6,000-Person trial tests smarter scopes

NCT ID NCT05762991

Recruiting now Diagnosis Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether artificial intelligence (AI) can help doctors better detect H. pylori infection and precancerous stomach changes during routine endoscopy. The goal is to see if AI assistance can reduce deaths from stomach cancer. The trial will enroll 6,000 adults aged 20–80 who are already scheduled for an endoscopy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Artificial intelligence software for endoscopy interpretation
What this could lead to: If successful, AI-assisted endoscopy could become a standard tool to catch stomach cancer earlier and reduce deaths from the disease.
What could go wrong: This is a large trial, but AI may not improve detection enough to lower death rates. Results depend on real-world use and follow-up over many years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease preneoplastic lesion gastric cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HELICOBACTER PYLORI INFECTION PREMALIGNANT LESION

Contacts and locations

Locations

Yi-Chia Lee
RECRUITING

Taipei, 10015, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.